center expans weigh
margin growth trend
china licens dynam inorgan center addit
weigh result underli plasma growth trend
look solid margin pressur margin
stori could improv pt
revenu line margin miss grifol report revenu
line mse repres organ growth line mse
bp momentum deceler sever dynam china licens time
mix biotest revenu recognit drove varianc segment delv
gross margin came pt
estim declin bp q/q pt y/i larg attribut center
acquisit biotest/haema china licens issu mix higher plasma
collect cost ep came estim primarili
result lower oper margin pleas see exhibit reconcili
walk bioscienc dynam quarter implic
bioscienc growth came estim reflect pt
momentum deceler delay renew process certain
licens china impact albumin sale estim pt headwind
bioscienc growth quarter resolv
taken conserv approach model bioscienc growth
easiest comp year momentum ramp throughout year
protein trend continu q/q ig see doubl digit growth grow
high singl digit pdfviii declin doubl digit look
chang profil includ modest ig growth moder perhap
lower rate pdfviii declin given comp year
improv albumin throughout year remind similar event
relat china licens happen year ago grifol bioscienc busi
acceler later quarter put take effect net
think bioscienc could continu grow similar
level see solid underli fundament
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
thought segment diagnost forecast growth line
market growth continu model doubl digit growth hospit though
smaller busi model chang substanti
suppli line expect quarterli run rate busi
go forward step number
includ month biotest plasma estim includ
revenu model increment y/i suppli
revenu notabl driver growth drive pt y/i
growth model organ growth overal
margin weaker could improv gross margin
big neg surpris quarter decreas bp q/q bp
decreas inorgan center addit includ month biotest
recognit discuss remain bp like come
combin china albumin issu ig mix higher collect cost
vocal inorgan center addit higher collect cost
margin headwind magnitud item surpris gross
margin like see continu pressur inorgan center addit
mix improv back half along collect cost
volum scale net model sequenti improv throughout
quarterli gross margin level comfort
year expect spend increas slightli given grifol focu
initi ambar preciosa net model oper
margin year pt decresa level year
howev oper margin repres sequenti
y/i improv throughout ep estim move
prior primarili result lower margin
updat nexsi system increment posit side
commentari ig growth next year modestli
commentari plasma market growth grifol remain confirmatori
around nexsi yield improv relat broader
commerci contract visibl timelin limit
consist haemonet model includ grifol
contribut see tortois hare detail
strateg updat shanghai raa haema/biotest novemb grifol
indic start convers shanghai raa make possibl
invest compani contribut fulli own us subsidiari grifol
diagnost solut subsidiari continu remain wait-and-
see mode if/how may come fruition separ end
grifol agre sell haema ag biotest us scranton enterpris
exclus irrevoc call option compani
sens strategi intend remov margin strain p/l
collect asset reach scale updat today indic grifol continu
consolid full oper result compani chang
 nonminority/noncontrol interest
margin headwind remain stori could look
brighter becom convinc sustain growth
particularli bioscienc growth last sever quarter rel
underweight thesi predic lower margin expans versu
rest coverag quarter result reinforc grifol
margin headwind work near term howev
margin pictur could brighter effici scale/improv
headwind anniversari beyond expir biotest/haema third parti
contract estim could drive materi inflect margin
year nexsi contract could present upsid margin estim
interim price target move cycl lower margin
model continu reflect multipl ep
grifol histor turn premium eu pharma continu expect fcrn
worri keep multipl constrain see fcrn risk plasma
provid convert price target usd assum adr
discount line histor averag reach price target
margin focu
margin focu
price target adr assum class share
trade one year forward earn grifol histor
turn premium european pharma adr trade
discount class share consist averag valuat
spread past sever year
new plasma bull market bioscienc growth push doubl digit
high singl digit sustain strong result albumin
bolster rebound ivig oper margin reach valuat
gap close
growth leverag upsid remain constrain pipelin catalyst
scarc plasma growth remain slightli elev return long-term
trend diagnost limit growth profil margin pressur
recent acquisit fcrn year away impact autoimmun
indic multipl
bioscienc growth slow sustain market pressur factor viii renew
competit larger incumb smaller player drive plasma
growth rate low singl digit slower growth price pressur
busi hamper overal growth valuat spread widen
underweight rate driven
combin limit upsid catalyst
margin pressur less upsid versu
rest coverag
bear case scenario scig cidp
rabi play plasma growth could push
low end mid singl digit
upsid pipelin catalyst scarc
see prospect albumin alzheim
low key data event year
ebit margin
everi bp ebit margin translat
ep
bioscienc growth growth grifol
bioscienc divis account
revenu key driver perform
assum spread remain around long
term averag
risk achiev price
narrow valuat spread adr vs
upsid estim
stabil competit situat us ivig
could support favor price trend
million except ep
euro million except per share data
good sold
share income/loss equiti account investe
net incom attribut common
loss attribut non-control interest
euro million except per share data
euro million except per share data
cash equival
trade receiv
properti plant equip net
goodwil intang asset
invest equiti account investe
debt associ
profit attribut parent
equiti attribut parent
euro million except per share data
profit tax
adjust
amort depreci
chang oper work capit
cash flow use oper activ
payment invest
group compani busi unit
properti plant equip intang asset
properti plant equip
proce sale properti plant equip
invest activ
proce payment equiti instrument
acquisit treasuri stock
dispos treasuri stock
redempt repay
proce payment financi liabil intrument
dividend interest equiti instrument paid receiv
payment financ activ
financ activ
effect exchang rate chang
begin period
end period
